GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform. More Details
Excellent balance sheet with high growth potential.
Share Price & News
How has GW Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GWPH's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: GWPH underperformed the US Pharmaceuticals industry which returned 10.8% over the past year.
Return vs Market: GWPH underperformed the US Market which returned 18.3% over the past year.
Price Volatility Vs. Market
How volatile is GW Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StHere's What GW Pharmaceuticals plc's (NASDAQ:GWPH) Shareholder Ownership Structure Looks Like
1 month ago | Simply Wall StDespite Lacking Profits GW Pharmaceuticals (NASDAQ:GWPH) Seems To Be On Top Of Its Debt
2 months ago | Simply Wall StWhen Can We Expect A Profit From GW Pharmaceuticals plc (NASDAQ:GWPH)?
Is GW Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GWPH ($95) is trading below our estimate of fair value ($514.11)
Significantly Below Fair Value: GWPH is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: GWPH is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: GWPH is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GWPH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GWPH is overvalued based on its PB Ratio (4.1x) compared to the US Pharmaceuticals industry average (3x).
How is GW Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GWPH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: GWPH is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: GWPH's is expected to become profitable in the next 3 years.
Revenue vs Market: GWPH's revenue (26.5% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: GWPH's revenue (26.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GWPH's Return on Equity is forecast to be low in 3 years time (17%).
How has GW Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GWPH is currently unprofitable.
Growing Profit Margin: GWPH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GWPH is unprofitable, and losses have increased over the past 5 years at a rate of 4.4% per year.
Accelerating Growth: Unable to compare GWPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GWPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.6%).
Return on Equity
High ROE: GWPH has a negative Return on Equity (-7.74%), as it is currently unprofitable.
How is GW Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: GWPH's short term assets ($687.7M) exceed its short term liabilities ($118.5M).
Long Term Liabilities: GWPH's short term assets ($687.7M) exceed its long term liabilities ($35.1M).
Debt to Equity History and Analysis
Debt Level: GWPH's debt to equity ratio (1.2%) is considered satisfactory.
Reducing Debt: GWPH's debt to equity ratio has reduced from 3.4% to 1.2% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GWPH has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if GWPH has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is GW Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GWPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GWPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GWPH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GWPH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GWPH's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Justin Gover (49 yo)
Mr. Justin D. Gover, BSc, MBA has been the Chief Executive Officer of GW Pharmaceuticals PLC since January 1999. Mr. Gover is responsible for managing GW Pharmaceuticals’s operations, equity financing and ...
CEO Compensation Analysis
Compensation vs Market: Justin's total compensation ($USD7.86M) is above average for companies of similar size in the US market ($USD5.61M).
Compensation vs Earnings: Justin's compensation has increased whilst the company is unprofitable.
|CEO & Executive Director||21.75yrs||US$7.86m||0.70% |
|Chief Financial Officer||3.58yrs||US$2.73m||0.033% |
|Chief Legal Officer||3.25yrs||US$2.89m||0.0098% |
|Chief Medical Officer||3.42yrs||US$3.00m||0.018% |
|Chief Operating Officer||8yrs||US$763.06k||0.00067% |
|Vice President of Investor Relations||7.58yrs||no data||no data|
|Chief Human Resources Officer||1.25yrs||no data||no data|
|Head of Discovery Research||3.42yrs||no data||no data|
|U.S. Chief Commercial Officer||1.5yrs||no data||0.018% |
|MD of UK & Company Secretary||13.75yrs||US$705.86k||0.010% |
|Pharmaceutical Development Advisor||no data||no data||no data|
Experienced Management: GWPH's management team is considered experienced (3.5 years average tenure).
|CEO & Executive Director||21.75yrs||US$7.86m||0.70% |
|Independent Director||7.67yrs||US$374.84k||0.0019% |
|Non-Executive Director||0.083yr||no data||no data|
|Independent Deputy Chairman & Lead Independent Director||13.75yrs||US$372.77k||0.0074% |
|Founder & Executive Chairman||22.75yrs||US$3.92m||1.51% |
|Independent Director||2.83yrs||US$345.77k||0% |
|Independent Director||2.83yrs||US$357.82k||0.0017% |
|Independent Director||2.83yrs||US$349.96k||0.0018% |
Experienced Board: GWPH's board of directors are considered experienced (5.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
GW Pharmaceuticals plc's company bio, employee growth, exchange listings and data sources
- Name: GW Pharmaceuticals plc
- Ticker: GWPH
- Exchange: NasdaqGM
- Founded: 1998
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.958b
- Shares outstanding: 31.14m
- Website: https://www.gwpharm.com
Number of Employees
- GW Pharmaceuticals plc
- Sovereign House
- Vision Park
- CB24 9BZ
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|GWPR.F||OTCPK (Pink Sheets LLC)||Ordinary Shares||US||USD||Jun 2001|
|GWPH||NasdaqGM (Nasdaq Global Market)||Yes||ADS EACH REPR 12 SHS||US||USD||May 2013|
|GW2A||DB (Deutsche Boerse AG)||Yes||ADS EACH REPR 12 SHS||DE||EUR||May 2013|
|0IT7||LSE (London Stock Exchange)||Yes||ADS EACH REPR 12 SHS||GB||USD||May 2013|
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform. Its lead product is Epidio ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/25 00:56|
|End of Day Share Price||2020/10/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.